SILO

+ Watchlist + Portfolio

Silo Pharma, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.86
52-Week Range: $2.58 – $15.15
Market Cap: $4.35M
P/E (TTM): —
EPS (TTM): -3.58
Dividend Yield: —

Advanced Metrics

Price/Book: 0.52
PEG Ratio: —
Return on Equity: -91.23%
Return on Assets: -44.25%
Gross Margin: -14.77%
Operating Margin: -8250.46%
Profit Margin: 0.00%
Current Ratio: 5.36
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-1.64M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-875.44K

SILO Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$72.10K	$72.10K	$72.10K	$72.10K
Cost of Revenue	$5.84K	$5.84K	$5.84K	$44.30K
Gross Profit	$66.26K	$66.26K	$66.26K	$27.81K
Research & Development	$1.29M	$845.09K	$2.37M	$2.16M
Selling, General & Admin	$2.43M	$3.08M	$2.40M	$2.15M
Operating Expenses	$3.71M	$3.92M	$4.77M	$4.31M
Operating Income	-$3.65M	-$3.86M	-$4.71M	-$4.28M
EBITDA	-$3.91M	-$3.63M	-$4.38M	-$4.18M
Pretax Income	-$3.91M	-$3.63M	-$4.39M	-$4.23M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$3.91M	-$3.70M	-$4.39M	-$4.23M
Diluted EPS	-25.65	-18.00	-17.85	-7.50
Diluted Shares	152282	205324	245359	558818

SILO Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$11.37M	$3.52M	$3.91M	$4.75M
Receivables	$66.01K	$0.00	—	—
Current Assets	$11.57M	$7.68M	$7.11M	$7.39M
Total Assets	$11.64M	$7.75M	$7.41M	$7.61M
Current Liabilities	$436.32K	$775.59K	$1.66M	$650.18K
Total Liabilities	$1.30M	$1.57M	$2.38M	$1.30M
Retained Earnings	-$7.17M	-$10.87M	-$15.26M	-$19.49M
Shareholders' Equity	$10.34M	$6.18M	$5.03M	$6.31M
Working Capital	$11.14M	$6.91M	$5.46M	$6.74M

SILO Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$3.50M	-$3.22M	-$3.83M	-$4.66M
Capital Expenditure	—	—	—	-$574.92K
Free Cash Flow	-$3.50M	-$3.22M	-$3.83M	-$5.24M
Depreciation & Amortisation	—	$0.00	$6.18K	$11.44K
Stock-Based Compensation	$156.05K	$14.13K	$0.00	$117.02K
Investing Cash Flow	$86.71K	-$4.15M	$973.78K	$644.02K
Financing Cash Flow	$4.94M	-$471.12K	$3.24M	$4.86M
Share Repurchases	$0.00	-$471.12K	-$173.11K	$0.00
Net Change in Cash	$1.53M	-$7.84M	$381.49K	$842.90K

SILO Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$18.03K	$18.02K	$18.02K	$18.03K	$18.03K
Cost of Revenue	$1.46K	$1.46K	$20.69K	$20.69K	$20.69K
Gross Profit	$16.57K	$16.57K	-$2.66K	-$2.66K	-$2.66K
Research & Development	$593.96K	$717.25K	$543.62K	$306.00K	$1.01M
Selling, General & Admin	$516.73K	$547.87K	$605.19K	$477.86K	$578.73K
Operating Expenses	$1.11M	$1.27M	$1.15M	$783.86K	$1.59M
Operating Income	-$1.09M	-$1.25M	-$1.15M	-$786.52K	-$1.59M
EBITDA	-$1.03M	-$1.20M	-$1.11M	-$845.89K	-$1.64M
Pretax Income	-$1.03M	-$1.20M	-$1.11M	-$881.53K	-$1.65M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$1.03M	-$1.20M	-$1.11M	-$881.53K	-$1.65M
Diluted EPS	-3.45	-2.85	-1.80	—	-1.80
Diluted Shares	298963	418648	622089	—	913947

SILO Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$3.14M	$4.33M	$3.92M	$4.75M	$3.90M
Current Assets	$5.60M	$6.37M	$6.16M	$7.39M	$6.80M
Total Assets	$5.90M	$6.65M	$6.38M	$7.61M	$7.02M
Current Liabilities	$1.19M	$1.05M	$708.34K	$650.18K	$704.85K
Total Liabilities	$1.89M	$1.74M	$1.38M	$1.30M	$1.34M
Retained Earnings	-$16.30M	-$17.50M	-$18.61M	-$19.49M	-$21.14M
Shareholders' Equity	$4.01M	$4.92M	$5.01M	$6.31M	$5.68M
Working Capital	$4.42M	$5.32M	$5.46M	$6.74M	$6.10M

SILO Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.64M	-$1.29M	-$955.49K	-$780.28K	-$822.62K
Capital Expenditure	—	—	—	—	-$49.99K
Free Cash Flow	-$1.64M	-$1.29M	-$955.49K	-$1.36M	-$872.61K
Depreciation & Amortisation	$3.09K	$2.47K	$2.94K	$2.94K	$2.94K
Stock-Based Compensation	$0.00	$17.45K	$47.27K	$52.31K	$56.62K
Investing Cash Flow	$871.38K	$388.10K	-$95.47K	-$519.99K	-$23.56K
Financing Cash Flow	$0.00	$2.09M	$634.92K	$2.13M	—
Share Repurchases	$0.00	$0.00	$0.00	$0.00	—
Net Change in Cash	-$768.92K	$1.20M	-$416.05K	$831.07K	-$846.19K

Market Snapshot

About

Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company is developing treatments for chronic pain, PTSD, and other neuropsychiatric conditions. Silo Pharma aims to create novel formulations and delivery methods for psychedelic and non-psychedelic compounds.